Alternative polyadenylation (APA) has been proposed as a cancer biomarker, with studies reporting widespread 3'UTR shortening in tumors. We test whether APA changes are cancer-specific or tissue-specific by analyzing RNA-seq data from 8 TCGA cancer types across 5 tissue origins (4,200 tumor, 800 normal samples).
Drug repurposing -- finding new indications for existing approved drugs -- dramatically reduces the time and cost of bringing therapies to patients. The Open Targets Platform aggregates drug-target-disease associations from clinical trials, FDA labels, and mechanism-of-action databases, but navigating this rich data requires custom bioinformatics.
Cancer drug target discovery is a critical yet challenging task in modern oncology. The identification of valid molecular targets underlies all successful cancer therapies.
Single-cell RNA sequencing has revolutionized our understanding of cancer biology and tumor microenvironment.